Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 3/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.74 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.74 |
| ▸ | THRB | P10828 | 1/20 | 0.74 |
| ▸ | BLM | P54132 | 1/20 | 0.74 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.74 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.74 |
| ▸ | CNR1 | P21554 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL375483 | 1.00 | CNR2 (0.74) | CNR2SMN1; SMN2KCNK3ALDH1A1THRB | |
| SCHEMBL5145799 | 0.95 | ALDH1A1 (0.68) | CNR2SMN1; SMN2KCNK3ALDH1A1THRB | |
| SCHEMBL11872018 | 0.95 | ALDH1A1 (0.68) | CNR2SMN1; SMN2KCNK3ALDH1A1THRB | |
| SCHEMBL5682652 | 0.95 | ALDH1A1 (0.68) | CNR2SMN1; SMN2KCNK3ALDH1A1THRB | |
| SCHEMBL653624 | 0.95 | ALDH1A1 (0.68) | CNR2SMN1; SMN2KCNK3ALDH1A1THRB | |
| SCHEMBL2225404 | 0.90 | ASAH2 (0.68) | CNR2SMN1; SMN2KCNK3ALDH1A1THRB | |
| SCHEMBL6846748 | 0.90 | ASAH2 (0.68) | CNR2SMN1; SMN2KCNK3ALDH1A1THRB | |
| SCHEMBL9109309 | 0.90 | ASAH2 (0.68) | CNR2SMN1; SMN2KCNK3ALDH1A1THRB | |
| SCHEMBL1147692 | 0.90 | ASAH2 (0.68) | CNR2SMN1; SMN2KCNK3ALDH1A1THRB | |
| SCHEMBL6534948 | 0.89 | CNR2 (0.76) | CNR2SMN1; SMN2KCNK3ALDH1A1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112280809-B | A two-step method for preparing cannabinoid | 江南大学 | 2023-02-24 | — | — | CN | claimed |
| CN-112280809-A | A two-step method for preparing cannabinoid | 江南大学 | 2021-01-29 | — | — | CN | claimed |
| CN-108272783-B | Esters for the treatment of ocular inflammatory disorders | 庄臣及庄臣视力保护公司 | 2020-11-17 | — | — | CN | claimed |
| CN-108272783-A | Ester for treating ophthalmic inflammatory illness | 庄臣及庄臣视力保护公司 | 2018-07-13 | — | — | CN | claimed |
| CN-118251203-A | Liquid composition of ceramide and palmitoyl amide | 尤尼法尔蔻股份有限公司 | 2024-06-25 | — | — | CN | disclosed |
| US-12012375-B2 | Prostaglandin F2 alpha derivatives for decreasing intraocular pressure | GURUS BIOPHARM LIMITED LIABILITY COMPANY (RU) | 2024-06-18 | — | — | US | disclosed |
| CN-118121577-A | Method for treating substance abuse | 感知神经科学公司 | 2024-06-04 | — | — | CN | disclosed |
| CN-112154139-B | Prostaglandin F2 alpha derivatives for ocular hypotension | 古鲁生物制药有限公司 | 2023-11-07 | — | — | CN | disclosed |
| CN-110662604-B | Polymer sorbents, preparation and use thereof | 埃费隆有限公司 | 2023-08-04 | — | — | CN | disclosed |
| WO-2023089557-A1 | LIQUID COMPOSITION OF CERAMIDES AND PALMITIC ACID AMIDES | UNIFARCO S.P.A. (IT) | 2023-05-25 | — | — | WO | disclosed |
| CN-115927586-A | Kit for detecting Siglec fusion mutant gene and GBS pathogenic gene and detection method thereof | 北京清华长庚医院 | 2023-04-07 | — | — | CN | disclosed |
| CN-112280809-B | A two-step method for preparing cannabinoid | 江南大学 | 2023-02-24 | — | — | CN | disclosed |
| US-20030166900-A1 | Methods of using 18903 to treat pain and pain-related disorders | MILLENNIUM PHARMACEUTICALS, INC. | 2003-09-04 | — | — | US | disclosed |
| WO-2002074321-A1 | COMPOSITION COMPRISING COCOA AND A DOPAMINE D2 RECEPTOR AGONIST | N.V. NUTRICIA (NL) | 2002-09-26 | — | — | WO | disclosed |
| WO-2002044357-A2 | METHODS OF USING 18903 TO TREAT PAIN AND PAIN-RELATED DISORDERS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-06-06 | — | — | WO | disclosed |
| EP-0670826-B1 | FATTY ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | YISSUM RES DEV CO (IL) | 2000-04-26 | — | — | EP | disclosed |
| US-5618955-A | ANTIINFLAMMATORY AGENTS, ANALGESICS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1997-04-08 | — | — | US | disclosed |
| EP-0670826-A4 | FATTY ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | YISSUM RES DEV CO (IL) | 1996-08-14 | — | — | EP | disclosed |
| EP-0670826-A1 | FATTY ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1995-09-13 | — | — | EP | disclosed |
| WO-1994012466-A1 | FATTY ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1994-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12012375-B2 | Prostaglandin F2 alpha derivatives for decreasing intraocular pressure | PTGS1, PTGIS, PTGS2 | CNR2 346/4885SMN1; SMN2 4245/4885KCNK3 2542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.